Excluding autos, prices fell 0.4%, also far off the consensus forecast for a 0.3% increase.
Related Posts
Leerink upgrades this beaten-down biotech stock, says investors should buy the dip
Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
American homeowners are wasting more space than ever before
The number of extra bedrooms — defined as a bedroom in excess of the number of people in a home, and even including one for […]